Itoco Inc. (ITMC) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerItoco Inc. (ITMC) trades at $0.0001. Itoco Inc. is a biotechnology company focused on the medical cannabis sector, engaging in the processing, production, and distribution of related products. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for ITMC: ITMC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Itoco Inc. (ITMC) Healthcare & Pipeline Overview
Itoco Inc., operating in the medical cannabis sector, focuses on processing, production, and distribution, distinguishing itself in a competitive market with a history rooted in mining before its strategic shift to biotechnology. Based in Reno, Nevada, the company navigates the evolving regulatory landscape of the cannabis industry.
What Is the Investment Thesis for ITMC?
Itoco Inc. presents a high-risk, high-reward investment opportunity within the volatile medical cannabis sector. With a market capitalization of $0.00B and a negative P/E ratio of -0.01, the company's financial performance requires careful scrutiny. A key value driver will be Itoco's ability to scale production and distribution effectively. Upcoming catalysts include potential regulatory changes in Nevada and expansion into new markets. However, the company's negative beta of -1.11 suggests a potential disconnect from broader market trends, and the absence of a dividend reflects its current stage of development. Investors should closely monitor Itoco's cash flow, debt levels, and ability to navigate the complex regulatory environment.
Based on FMP financials and quantitative analysis
ITMC Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with significant growth potential but also higher risk.
- Negative P/E ratio of -0.01 suggests the company is currently not profitable, requiring further investigation into its financial performance.
- Beta of -1.11 indicates a negative correlation with the market, meaning the stock price may move in the opposite direction of the overall market.
- The company has no dividend yield, which is common for growth-oriented companies in the biotechnology sector that reinvest earnings.
- Transition from mining to medical cannabis in 2018 demonstrates a strategic shift to capitalize on a growing market.
Who Are ITMC's Competitors?
ITMC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.97 | +2.26% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $17.13 | +0.29% | $90.6M | 83 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.54 | +1.06% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.61 | -1.75% | $206M | 67 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | +0.00% | $218M | 73 5-pillar |
| NAGE Niagen Bioscience Inc | $2.67 | -4.13% | $222M | 68 5-pillar |
| QTTB Q32 Bio Inc. | $8.45 | +2.67% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.31 | +1.67% | $571M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ITMC's Key Strengths?
Strategic shift to a high-growth industry (medical cannabis).
- Location in Nevada, a state with a well-established medical cannabis program.
- Focus on processing, production, and distribution within the cannabis value chain.
- Relatively small size allows for agility and adaptability.
What Are ITMC's Weaknesses?
Limited financial resources and market capitalization.
- Lack of profitability and negative P/E ratio.
- Intense competition in the medical cannabis industry.
- Reliance on a single state market (Nevada).
What Are the Key Risks for ITMC?
Financial-distress signal — its Altman Z-Score of -24.85 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory uncertainty and potential changes in cannabis laws.
- Intense competition in the medical cannabis industry.
- Limited access to capital and funding.
- Negative public perception and stigma associated with cannabis.
- Operational challenges and supply chain disruptions.
What Are ITMC's Competitive Advantages?
- Proprietary cannabis formulations (if any).
- Established distribution network within Nevada.
- Strategic partnerships with key industry players (if any).
- Brand recognition and reputation (if any).
What Does ITMC Do?
Itoco Inc., headquartered in Reno, Nevada, is a biotechnology company specializing in the medical cannabis industry. Founded initially as Itoco Mining Corporation, the company underwent a strategic transformation in May 2018, rebranding itself as Itoco Inc. and pivoting its business model to capitalize on the burgeoning medical cannabis market. This transition reflects a significant shift from resource extraction to biotechnology, aligning with the growing acceptance and legalization of cannabis for medicinal purposes. Itoco Inc. focuses on the processing, production, and distribution of medical cannabis products. The company aims to provide patients and healthcare providers with access to high-quality cannabis-based treatments. While specific product details are not available, the company likely engages in various aspects of the cannabis value chain, from cultivation and extraction to formulation and distribution. Given its relatively small size of 47 employees, Itoco Inc. likely outsources some aspects of its operations or focuses on niche segments within the broader medical cannabis market. The company's location in Nevada provides access to a state with a well-established medical cannabis program, offering both opportunities and challenges in a competitive landscape. As a smaller player in the biotechnology sector, Itoco Inc. faces the task of differentiating itself through product innovation, strategic partnerships, or efficient operations.
What Products and Services Does ITMC Offer?
- Processes medical cannabis plants.
- Produces various medical cannabis products.
- Distributes medical cannabis products to dispensaries and patients.
- Engages in cultivation activities (potentially outsourced or in-house).
- Formulates cannabis-based therapies and treatments.
- Navigates the regulatory landscape of the medical cannabis industry.
- Markets and sells its products to healthcare providers and patients.
How Does ITMC Make Money?
- Generates revenue through the sale of medical cannabis products.
- Potentially operates cultivation facilities or contracts with growers.
- Focuses on processing and manufacturing cannabis-based products.
- Distributes products through a network of dispensaries and potentially direct-to-patient channels.
What Industry Does ITMC Operate In?
Itoco Inc. operates within the rapidly evolving medical cannabis industry, a segment of the broader biotechnology sector. The industry is characterized by increasing legalization, growing acceptance of cannabis-based treatments, and significant investment activity. However, it also faces regulatory hurdles, intense competition, and pricing pressures. Companies like Itoco Inc. must navigate a complex landscape of state and federal regulations while differentiating themselves through product innovation, efficient operations, and strategic partnerships. The medical cannabis market is projected to experience substantial growth in the coming years, driven by increasing patient demand and expanding access to cannabis-based therapies.
Who Are ITMC's Key Customers?
- Patients seeking medical cannabis treatments.
- Dispensaries that sell medical cannabis products.
- Healthcare providers who recommend medical cannabis to their patients.
- Potentially pharmaceutical companies (through partnerships).
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Itoco Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.85 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Itoco Inc. stands at 199.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 17.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.85 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Itoco Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Reno, US. The company is led by CEO Gilbert Paez. ITMC has traded publicly since 2009.
ITMC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ITMC Latest News
No recent news available for ITMC.
ITMC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ITMC.
Price Targets
Wall Street price target analysis for ITMC.
ITMC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ITMC; grades run from A+ (80-100) to F (below 30).
Leadership: Gilbert Paez
CEO
Gilbert Paez is the CEO of Itoco Inc., responsible for managing the company's operations and strategic direction within the medical cannabis sector. Information regarding Mr. As CEO, he oversees a team of 47 employees and is responsible for guiding the company's growth and navigating the complex regulatory landscape of the cannabis industry.
Track Record: Due to limited information available, Gilbert Paez's track record and key achievements at Itoco Inc. Assessing his performance requires further data on the company's financial results, operational milestones, and strategic initiatives under his leadership.
ITMC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Itoco Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may be subject to greater risks due to lack of transparency and oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited regulatory oversight and investor protection.
- Verify the company's legal registration and compliance with state regulations.
- Obtain and review any available financial statements and reports.
- Assess the company's management team and their experience.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive position and industry outlook.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company's registration and licensing in Nevada.
- Operational facilities and activities in the medical cannabis sector.
- Presence of a management team and employees.
- Publicly available information, even if limited, about the company's business.
- Engagement with the medical cannabis community and industry events (if any).
Itoco Inc. Healthcare Stock: Key Questions Answered
What do analysts say about ITMC stock?
As of 2026-03-18, there is no available analyst coverage or consensus on ITMC stock. The company's micro-cap status and OTC listing likely contribute to the lack of analyst attention.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on Itoco Inc.'s financials and operations.
- OTC listing increases the risk and uncertainty associated with the investment.
- Lack of analyst coverage limits the availability of independent research.